Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04995094
Recruitment Status : Withdrawn (Enrollment challenges, study not feasible)
First Posted : August 6, 2021
Last Update Posted : November 5, 2021
Information provided by (Responsible Party):
HiberCell, Inc.

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : February 18, 2023
Estimated Study Completion Date : May 18, 2023